Kisspeptin-10
Also known as: Kp-10, Metastin 45-54, Kisspeptin-112-121
Kisspeptin-10 (also called Kp-10 or Metastin 45-54) is a kisspeptin fragment in the GnRH Modulator class. Kisspeptin-10 is the C-terminal decapeptide fragment of the KISS1 gene product and retains full activity at KISS1R, the G protein-coupled receptor formerly called GPR54.
For research use only.
Key Facts
- CAS
- 374675-21-5
- Molecular Weight (MW)
- 1302.5 g/mol
- Half-life
- ~4 minutes
- FDA status
- Not Approved
- Evidence level
- Limited Human Evidence
- Human dose established
- Yes
- Administration Route
- Intravenous
- Frequency
- Single bolus or short infusion in the published studies
- Last updated
- Sep 26, 2026
- Reviewed
- Aug 30, 2026
- Targets
- KISS1R (GPR54)
Vendor price snapshot
Each vendor counts once, at the median price per mg of its own listings; the typical range is the middle half of vendors. From public vendor listings collected between Dec 2025 and Sep 2026, so confirm the live price on the vendor site. Peptide Library does not sell peptides.
- Vendors listing this peptide
- 8
- Listed offers
- 14
- Median price per mg
- $7.75/mg
- Typical $6.00–$11.38/mg
Research summary
Decapeptide KISS1 fragment that stimulates GnRH release. Used in reproductive-endocrine research. WADA lists kisspeptin and agonists as S2. Not FDA-approved.
Peptide Library's Kisspeptin-10 profile summarises 5 cited studies listed in the Science section, the compound's regulatory status, and research-protocol parameters reported for it. It is a research reference, not medical advice.
Kisspeptin-10 dosage chart
Kisspeptin-10 itself has been given to humans only in short academic physiology studies, by intravenous bolus at doses on the order of 0.24 nmol/kg; a registered trial of its effect on insulin secretion has posted no results. Two further human studies often cited for it — an intranasal study at 12.8 nmol/kg and a bone-metabolism infusion — used kisspeptin-54, the 54-residue parent peptide, and are not evidence for the 10-residue fragment. No product is approved and no repeated-dosing regimen has been established.
| Human dosing established | Yes |
|---|---|
| Studied dose range | 0.24 nmol/kg intravenous bolus (the only published kisspeptin-10 human dose) |
| Route | Intravenous |
| Frequency | Single bolus or short infusion in the published studies |
| Duration studied | Acute, single-session protocols |
| Evidence level | Limited Human Evidence |
| Last reviewed | 2026-09-26 |
Research-reported dosing
Doses as studied, one row per regimen. Different trials used different regimens; they are listed separately rather than averaged.
| Study / context | Population | Dose | Route | Frequency | Duration | Outcome studied | Source |
|---|---|---|---|---|---|---|---|
| Intravenous bolus study of kisspeptin-112-121, i.e. kisspeptin-10 (Galbiati et al., 2025)Clinical trial · Human physiology study | Healthy adults (n=12, 50% female) | 0.24 nmol/kg bolus of kisspeptin-112-121 | Intravenous | Single bolus | Acute | Oxytocin response, by sex | Sex-dependent increases in oxytocin levels in response to intravenous kisspeptin in humans. Eur J Endocrinol. 2025. |
| NCT03771326 — insulin secretion in menClinical trial · Registered trial, completed, no results posted | Men (n=14) | Per trial protocol | Intravenous | — | — | Insulin secretion | NCT03771326 — KP-10 and Insulin Secretion in Men |
Preclinical and analog research
Not human dosing evidence. Listed for completeness and never extrapolated to a human dose.
| Study / context | Population | Dose | Route | Frequency | Duration | Outcome studied | Source |
|---|---|---|---|---|---|---|---|
| Intranasal study (Mills et al., 2025) — used kisspeptin-54, the 54-residue parent, not kisspeptin-10Clinical trial · Human physiology study of the parent peptide (analog evidence)Studied an analog, not Kisspeptin-10 itself | Healthy adults across several study groups | 12.8 nmol/kg | Intranasal | Single administration | Acute | Luteinising hormone response | Intranasal kisspeptin administration rapidly stimulates gonadotropin release in humans. EBioMedicine. 2025. |
| Bone metabolism study (Comninos et al., 2022) — used kisspeptin-54, the 54-residue parent, not kisspeptin-10Clinical trial · Human physiology study of the parent peptide (analog evidence)Studied an analog, not Kisspeptin-10 itself | Healthy men | 1 nmol/kg/h intravenous infusion for 90 minutes (kisspeptin-54) | Intravenous | — | — | Bone formation and resorption markers | Acute Effects of Kisspeptin Administration on Bone Metabolism in Healthy Men. J Clin Endocrinol Metab. 2022. |
Where sources disagree
- Published human dosing is weight-based and given intravenously or intranasally in a laboratory setting, in nanomoles per kilogram. Kisspeptin-10 is sold for subcutaneous self-injection with fixed protocols commonly quoted around 100 mcg; those figures are several orders of magnitude away from the studied doses once converted, and no published study used that route.
- Kisspeptin-10 is the 112-121 fragment of kisspeptin-54. Studies are indexed under kisspeptin, KP-10, kisspeptin-112-121 and metastin, and evidence for the 54-residue parent is not automatically evidence for the 10-residue fragment.
- All published human work is acute and mechanistic — single doses measuring a hormone response over hours. Nothing establishes a repeated-dosing regimen or its safety over time.
Reconstitution
Common research vial sizes: 5 mg, 10 mg.
| Vial | Bacteriostatic water | Concentration | Per 0.01 mL |
|---|---|---|---|
| 5 mg | 2 mL | 2.5 mg/mL | 25 mcg per 0.01 mL |
| 10 mg | 2 mL | 5 mg/mL | 50 mcg per 0.01 mL |
These figures are arithmetic only — they convert a vial and a volume into a concentration. They are not a recommendation to take any dose.
Calculate reconstitution & dose →Handling & administration
- Reconstitution Guide
- 3 mL BAC for 5 mg vial
- Injection Sites
- Abdomen
- Concentration Example
- 5 mg / 3 mL = ~1.67 mg/mL
- Timing Notes
- Evenings
- Expected Onset
- 1-2 weeks
How to reconstitute Kisspeptin-10
- Check the vial size and diluent volume. The profile example for Kisspeptin-10 is: 3 mL BAC for 5 mg vial.
- Swab both vial stoppers and draw the bacteriostatic water into a sterile syringe.
- Add the water slowly down the inside wall of the peptide vial so it does not jet onto the powder, then swirl gently until the solution is clear. Do not shake.
- Record the resulting concentration: 5 mg / 3 mL = ~1.67 mg/mL.
- Label the vial with the date and concentration, refrigerate it (see Storage & stability below), and use the calculator preset to convert a dose in mcg into syringe units.
Sequence & molecular data
| Amino acid sequence | Tyr-Asn-Trp-Asn-Ser-Phe-Gly-Leu-Arg-Phe-NH₂ |
|---|---|
| Molecular formula | C63H83N17O14 |
| Molecular weight | 1302.5 g/mol |
| CAS number | 374675-21-5 |
| Half-life | ~4 minutes |
| Appearance | White lyophilized powder |
| Formulation | Lyophilized Powder |
| PubChem CID | 25240297 |
| FDA UNII | FS1N52VS3S |
| ChEMBL | CHEMBL376756 |
Identifiers link to the public PubChem, FDA Substance Registration (UNII), ChEMBL and DrugBank records for the same entity.
Science
Mechanism of Action
Kisspeptin-10 is the C-terminal decapeptide fragment of the KISS1 gene product and retains full activity at KISS1R, the G protein-coupled receptor formerly called GPR54. Kisspeptin neurons in the arcuate nucleus and preoptic area sit immediately upstream of GnRH neurons and are the principal gatekeeper of GnRH pulsatility, integrating sex steroid feedback, nutritional status and circadian input. Receptor activation on GnRH neurons depolarises them and triggers GnRH release, raising luteinising and follicle-stimulating hormone. Because the fragment is cleared within minutes, sustained stimulation in research settings requires infusion or repeated dosing.
Origin
Synthetic C-terminal kisspeptin fragment.
Targets
Studies
- Safety Evaluation of KP-10 (Metastin 45-54) Following once Daily Intravenous Administration for 14 Days in Dog
- The kisspeptin analog C6 elicits greater tachyphylaxis and transcriptional activation than kisspeptin-10 and -54
- Synthesis and characterisation of DOTA-kisspeptin-10 as a potential gallium-68/lutetium-177 pan-tumour radiopharmaceutical
- Investigating the detection of the novel doping‐relevant peptide kisspeptin‐10 in urine using liquid chromatography high‐resolution mass spectrometry
- Kisspeptin-10 binding to Gpr54 in osteoclasts prevents bone loss by activating Dusp18-mediated dephosphorylation of Src
Regulatory & research status
Kisspeptin-10 is not an FDA-approved product. It is sold for laboratory research and has no approved medical use.
| FDA status | Not Approved |
|---|---|
| Availability | Research-Only |
| WADA (sport) | Banned in Sport |
| Library classification | Research-Only |
Benefits
Kisspeptin-10 side effects
Kisspeptin-10 has only limited human data, so the list below is incomplete and its side-effect profile is not well established.
Side Effects
- Flushing
- LH surge effects
Contraindications
- Hormone-sensitive cancers
Stacking
Common stacking partners
Combinations that include Kisspeptin-10, with the proposed rationale, an evidence grade and what is not established, are catalogued in the peptide stacks directory.
Storage & stability
Lyophilized (freeze-dried) peptide powder is far more stable than the reconstituted solution. Keep sealed vials cold, dry and away from light; long-term storage is typically frozen, with short-term refrigeration for vials in use.
Once reconstituted in bacteriostatic water, keep the solution refrigerated, avoid repeated freeze–thaw cycles and agitation, and label the vial with the reconstitution date and concentration. Discard any solution that turns cloudy or shows particulates.
Degradation rates differ by sequence: peptides containing methionine, cysteine, asparagine or glutamine are more prone to oxidation and deamidation, so shelf life after reconstitution is compound-specific rather than universal.
Read the full guide: how to store peptides before and after reconstitution →
Source: Manning MC, Chou DK, Murphy BM, Payne RW, Katayama DS. Stability of protein pharmaceuticals: an update. Pharm Res. 2010;27(4):544–575. (PMID 20143256). General guidance for research handling; not product-specific instructions.
Kisspeptin-10: frequently asked questions
What is Kisspeptin-10?
Decapeptide KISS1 fragment that stimulates GnRH release. Used in reproductive-endocrine research. WADA lists kisspeptin and agonists as S2. Not FDA-approved.
How does Kisspeptin-10 work?
Kisspeptin-10 is the C-terminal decapeptide fragment of the KISS1 gene product and retains full activity at KISS1R, the G protein-coupled receptor formerly called GPR54. Kisspeptin neurons in the arcuate nucleus and preoptic area sit immediately upstream of GnRH neurons and are the principal gatekeeper of GnRH pulsatility, integrating sex steroid feedback, nutritional status and circadian input.
Is Kisspeptin-10 FDA approved?
No. Kisspeptin-10 is not approved by the FDA for any indication and is categorised as research-only. It has not been reviewed for safety or efficacy as a medicine, and published research should be read as investigation rather than established use.
What is the half-life of Kisspeptin-10?
Reported half-life for Kisspeptin-10 is ~4 minutes. Half-life describes how long the compound persists in circulation, not how long any effect lasts, and published figures vary with route of administration, formulation and the population studied.
What is the amino acid sequence of Kisspeptin-10?
Kisspeptin-10 has the sequence Tyr-Asn-Trp-Asn-Ser-Phe-Gly-Leu-Arg-Phe-NH₂, giving a chain of 11 amino acids. Its molecular formula is C63H83N17O14.
Is Kisspeptin-10 banned in sport?
Kisspeptin-10 is recorded here as prohibited in sport. Athletes subject to anti-doping rules should check the current WADA Prohibited List directly, since it is revised annually and classifications change.
References
- WADA Prohibited List 2026External reference
- Safety Evaluation of KP-10 (Metastin 45-54) Following once Daily Intravenous Administration for 14 Days in Dog — Int J Toxicol, 2021External reference
- The kisspeptin analog C6 elicits greater tachyphylaxis and transcriptional activation than kisspeptin-10 and -54 — Mol Cell Endocrinol, 2026External reference
- Synthesis and characterisation of DOTA-kisspeptin-10 as a potential gallium-68/lutetium-177 pan-tumour radiopharmaceutical — J Neuroendocrinol, 2025External reference
- Investigating the detection of the novel doping‐relevant peptide kisspeptin‐10 in urine using liquid chromatography high‐resolution mass spectrometry — Biomed Chromatogr, 2024External reference
- Kisspeptin-10 binding to Gpr54 in osteoclasts prevents bone loss by activating Dusp18-mediated dephosphorylation of Src — Nat Commun, 2024External reference
Related research, comparisons & guides
- hCG: What It Does in Men and Why It Is Not a Peptide
- Kisspeptin-10: The Upstream Switch of the Reproductive Axis
- Gonadorelin: GnRH Itself, and Why the Schedule Decides the Effect
- Enclomiphene: Not a Peptide, and That Matters
- Peptide stacks: combinations by research goalStacks
- Peptide dosage chart: dose, route and frequencyCategory
- Peptide calculator with the Kisspeptin-10 preset
- How to store peptides before and after reconstitution
Related peptides
Compiled by Peptide Library Editorial · Reviewed Aug 30, 2026 · Updated Sep 26, 2026 · Version 4
This Kisspeptin-10 profile is compiled from published literature (5 cited studies linked above), public regulatory records and chemical registries. It describes what research reports; it is not medical advice, and nothing here is a dosing recommendation for humans. Peptide Library does not sell peptides. Editorial policy · How profiles are compiled · Report an error
Track Kisspeptin-10 research, inventory and reconstitution in the free Peptide Library app. Get the app for iOS or Android →